ArticleInternational journal of radiation oncology, biology, physics2026
Impact of Tamoxifen Only After Lumpectomy for "Good-Risk" Duct Carcinoma In Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials.
Article in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2026.Breast care (Basel, Switzerland) · 2026Review
- AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025.Breast care (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
purposeThe NRG Oncology/Radiation Therapy Oncology Group (RTOG) 9804 trial randomized patients with "good-risk" ductal carcinoma in situ (DCIS) to radiation (RT) or no RT following lumpectomy. The Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E5194 trial had a comparable cohort observed without RT. Tamoxifen use was optional in both trials. This ancillary exploratory analysis combining both data sets assessed the effect of tamoxifen on ipsilateral breast recurrence (IBR) in "good-risk" DCIS treated with lumpectomy alone. METHODS AND MATERIALS: A combined database from the non-RT arm of NRG/RTOG 9804 and the "good-risk" cohort from E5194 (low- or intermediate-grade, ≤2.5 cm, excision margins ≥3 mm) was created, and distributions of patient and DCIS characteristics by tamoxifen use were compared by χ
resultsEight hundred and seventy-eight patients were analyzed (317 from NRG/RTOG 9804 and 561 from E5194). The use of tamoxifen overall was 43.1% (65.6% in NRG/RTOG 9804 and 30.3% in E5194). At a median follow-up of 14.85 years, there were 117 IBRs (65 invasive and 52 DCIS). There was a significant association for reduced IBR with tamoxifen use (P = .001); estimated 15-year IBR with tamoxifen is 11.4% (95% CI, 7.9-15.5) and without is 19.0% (15.3-22.9). Tamoxifen use was significantly associated with reduced invasive IBR (P = .0048) but not DCIS-IBR (P = .089). On multivariable analysis, patients who received tamoxifen were 46% less likely to have any IBR (hazard ratio, 0.54; 95% CI, 0.35-0.83; P = .0045), and 57% less likely to have invasive IBR (hazard ratio, 0.43; 95% CI, 0.24-0.77; P = 0.0042).
conclusionFor patients with "good-risk" DCIS treated with lumpectomy without RT, tamoxifen use was significantly associated with a reduction in IBR overall and invasive IBR, not DCIS-IBR.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.